ALN SOD
Alternative Names: ALN-SODLatest Information Update: 04 Oct 2024
At a glance
- Originator Alnylam Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference; Superoxide dismutase 1 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
Most Recent Events
- 06 Sep 2024 Phase-I clinical trials in Amyotrophic lateral sclerosis in Canada (Intrathecal) (NCT06351592)
- 02 Feb 2024 Regeneron Pharmaceuticals plans a phase I trial for Amyotrophic lateral sclerosis (ALS) in 2024
- 19 Nov 2021 Preclinical trials in Amyotrophic lateral sclerosis in USA, prior to November 2021